Growth Investments

Providing expansion capital to high growth life science companies

Strategy

Our approach to Growth Equity investments

We are an engaged investor in, and a partner to, life science companies at the leading edge of innovation.

We invest in companies harnessing the transformative power of biology and technology. In particular, we focus on investments in clinical diagnostics, industrial biotechnology, biologics supply chain, and healthcare IT.

We leverage our deep scientific knowledge, operational expertise and global network for the benefit of our portfolio companies.

We have evergreen capabilities that allow us to have a longer-term horizon, and be a true partner dedicated to enabling our portfolio companies to fulfil their potential.

Growth Investments

What we do

We invest in highly innovative, scalable life science companies that have recently reached, or are close to, the commercial stage, with strong long-term potential.

The combination of our long-term capital and sector expertise position us as an investor of choice for growth companies in the life science sector.

Growth Investments

What we do

We invest in highly innovative, scalable life science companies that have recently reached, or are close to, the commercial stage, with strong long-term potential.

The combination of our long-term capital and sector expertise position us as an investor of choice for growth companies in the life science sector.

As of 31 December 2021

  • € 250 M

    deployed across 11 new and four follow-on direct investments

  • € 1.1 bn

    Portfolio value at the end of 2021

  • € 330 M

    Increase in portfolio value since end of 2020

Growth Investments Portfolio

All teams

    Investment timeline

    Growth Investments

    Kate Farms

    Learn more
    Growth Investments May 2019

    Oxford Biomedica

    Novo Holdings has agreed to invest up to £53.5 million in new ordinary shares in Oxford Biomedica plc.

    Learn more
    Growth Investments May 2019

    MycoWorks

    Novo Holdings invests in Series A funding for MycoWorks.

    Learn more
    Growth Investments May 2019

    Tempus

    Novo Holdings announces it is the largest new investor in a $200 million Series F Financing of Tempus.

    Learn more
    Growth Investments June 2019

    Vestaron

    Novo Holdings announces it is the lead investor in the $40 million Series B Financing of Vestaron.

    Learn more
    Growth Investments August 2019

    LanzaTech

    Novo Holdings invests $72 million in sustainable products leader LanzaTech.

    Learn more
    Growth Investments December 2019

    Biomason

    Novo Holdings makes a multimillion dollar investment to acquire stake in US-based bioMASON

    Learn more
    Growth Investments April 2020

    Kebotix

    Kebotix partners with the private and public sector in harnessing the power of its breakthrough platform that combines artificial intelligence and robotic automation to discover chemicals and materials significantly faster and more affordably.

    Learn more
    Growth Investments May 2020

    Exscientia

    Novo Holdings leads USD 60m financing round in Exscientia.

    Learn more
    Growth Investments August 2020

    Mission Bio

    Novo Growth leads USD 70m Series C financing round in Mission Bio

    Learn more
    Growth Investments November 2020

    The Protein Brewery

    Novo Holdings leads EUR 22m Series A investment in The Protein Brewery, an innovative developer of protein-rich food ingredients.

    Learn more
    Growth Investments March 2021

    Deep Branch

    Learn more
    Growth Investments May 2021

    AMSilk

    Learn more
    Growth Investments June 2021

    Quanta

    Learn more
    Growth Investments July 2021

    Genomatica

    Learn more
    Growth Investments September 2021

    ZELP

    Learn more
    Growth Investments October 2021

    BIOMILQ

    Learn more
    Growth Investments January 2022

    Verana Health

    Learn more
    Growth Investments May 2022

    Invetx

    Learn more
    Growth Investments May 2022

    Elo Life Systems

    Learn more
    Growth Investments January 2023

    Evosep

    Learn more
    Growth Investments February 2023

    Aquafortus

    Learn more

    People

    Meet our team

    We are a dedicated growth equity team with strong industry and scientific knowledge and experience, based in San Francisco.

    Meet our team

    Contact

    Novo Growth*
    501 2nd Street, Suite 300
    San Francisco, CA 94107
    USA
    +1 (415) 552-6686

    *) Growth is a team of business professionals employed by Novo Holdings Equity US Inc., which is a separate legal entity that provides certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.